BACKGROUND:Budesonide (Entocort) is effective for the treatment of collagenous colitis. AIM: To assess the long-term outcome of patients after induction of clinical remission by budesonide treatment. METHODS:Fifty-one patients with chronic diarrhoea and histologically proven collagenous colitis were enrolled in randomized, placebo-controlled crossover trial using budesonide 9 mg daily for 6 weeks. Patients in clinical remission after either initial or crossover budesonide treatment were followed using standardized questionnaires. Clinical relapse was defined as five or more loose stools/day for at least 4 consecutive days. RESULTS: A total of 33 patients achieved clinical remission (85% per-protocol). During a median follow-up of 16 months, clinical relapse occurred in 20 patients (61%), after a median time of 2 weeks (range: 1-104, mean: 10 weeks). Patient age <60 years was identified as a significant risk factor for clinical relapse (OR = 7.4, P = 0.048). Budesonide was used for treatment of clinical relapse in 80% of patients achieving clinical response in all of them. CONCLUSIONS:Budesonide is effective in the treatment of collagenous colitis. Clinical relapses may occur in a considerable number of patients, particularly in those <60 years. Treatment of clinical relapse with budesonide appears to be an effective option.
RCT Entities:
BACKGROUND:Budesonide (Entocort) is effective for the treatment of collagenous colitis. AIM: To assess the long-term outcome of patients after induction of clinical remission by budesonide treatment. METHODS: Fifty-one patients with chronic diarrhoea and histologically proven collagenous colitis were enrolled in randomized, placebo-controlled crossover trial using budesonide 9 mg daily for 6 weeks. Patients in clinical remission after either initial or crossover budesonide treatment were followed using standardized questionnaires. Clinical relapse was defined as five or more loose stools/day for at least 4 consecutive days. RESULTS: A total of 33 patients achieved clinical remission (85% per-protocol). During a median follow-up of 16 months, clinical relapse occurred in 20 patients (61%), after a median time of 2 weeks (range: 1-104, mean: 10 weeks). Patient age <60 years was identified as a significant risk factor for clinical relapse (OR = 7.4, P = 0.048). Budesonide was used for treatment of clinical relapse in 80% of patients achieving clinical response in all of them. CONCLUSIONS:Budesonide is effective in the treatment of collagenous colitis. Clinical relapses may occur in a considerable number of patients, particularly in those <60 years. Treatment of clinical relapse with budesonide appears to be an effective option.
Authors: Dora Colussi; Behzad Salari; Kathleen O Stewart; Gregory Y Lauwers; James R Richter; Andrew T Chan; Luigi Ricciardiello; Hamed Khalili Journal: Scand J Gastroenterol Date: 2015-05-21 Impact factor: 2.423
Authors: Niki Daferera; Henrik Hjortswang; Simone Ignatova; Andreas Münch Journal: United European Gastroenterol J Date: 2019-08-20 Impact factor: 4.623
Authors: Tahir S Kafil; Tran M Nguyen; Petrease H Patton; John K MacDonald; Nilesh Chande; John Wd McDonald Journal: Cochrane Database Syst Rev Date: 2017-11-11
Authors: Andreas Münch; Curt Tysk; Johan Bohr; Ahmed Madisch; Ole K Bonderup; Ralf Mohrbacher; Ralph Mueller; Roland Greinwald; Magnus Ström; Stephan Miehlke Journal: J Crohns Colitis Date: 2015-12-30 Impact factor: 9.071
Authors: Nicole M Gentile; Adil A Abdalla; Sahil Khanna; Thomas C Smyrk; William J Tremaine; William A Faubion; Patricia P Kammer; William J Sandborn; Edward V Loftus; Darrell S Pardi Journal: Am J Gastroenterol Date: 2013-01-08 Impact factor: 10.864
Authors: Ahmed Madisch; Stephan Miehlke; Otto Eichele; Jenny Mrwa; Birgit Bethke; Eberhard Kuhlisch; Elke Bästlein; Georg Wilhelms; Andrea Morgner; Bernd Wigginghaus; Manfred Stolte Journal: Int J Colorectal Dis Date: 2007-09-02 Impact factor: 2.571